Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is in a strong financial position with $200 million in net cash and strong cash flow dynamics, providing potential for continued external growth in assets. Additionally, their pricing power, expansions in international markets, and growing salesforce also contribute to a positive outlook. With consistent double-digit organic top line growth, margin expansion, and strong cash flow, we believe LMAT deserves a premium valuation and would recommend buying shares during any potential dips.

Bears say

LeMaitre Vascular is projected to continue delivering solid financial results with double-digit organic revenue growth and increased EPS guidance, driven by strong sales performance in its international markets and the potential for growth within its medical device products such as Artegraft and RestoreFlow. However, potential headwinds in the pricing environment and slower than expected unit volume growth could impact the company's overall revenue growth in the short term. Additionally, the company's target of 170-180 sales representatives by 2026 may be difficult to achieve, potentially limiting future sales growth.

LeMaitre Vascular (LMAT) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 4 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.